Tubercular Drug Delivery Systems (PDF)
be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year
(QALY). Infectious diseases are one of the major to...
85 DeutschlandCard Punkte sammeln
- Lastschrift, Kreditkarte, Paypal, Rechnung
- Kostenloser tolino webreader
The disability-adjusted life year (DALY) is a generic measure of health effect that can
be used in cost-effectiveness analysis as an alternative to the quality-adjusted life year
(QALY). Infectious diseases are one of the major to cause significant losses of DALY and
QALY. Human infectious diseases are disorders that are triggered by the microorganisms
such as bacteria, fungi, viruses, or parasites. The majority of such diseases are contagious
and create a public health menace. There are several reasons why infectious diseases
are deadly diseases, and one of the primary reasons is the drug resistance developed
over time. Drug resistance-associated mutations are linked to increasing drug efflux,
modifications of the drugs, or their targets. Every year, new drugs are being approved by
FDA to treat infectious diseases. Nonetheless, the infectious diseases will undoubtedly
persist as permanent and main threats to humanity now and in the future, primarily
due to increased longevity that almost always comes at a cost of impaired immunity.
A total of four books are covered under the series of Infectious diseases.
. Malarial drug delivery systems
. Tubercular drug delivery systems
. Viral drug delivery systems
. Infectious disease drug delivery systems
The theme of the second book is Tuberculosis (TB). This book addresses the recent
trends in drug delivery for treating TB using new formulation technologies, and the
mechanism how it can prevent or delay the drug resistance. It covers current drug therapy
and new drug targeting approaches focusing on innovative trend-defining technologies
and drug delivery platforms. It is essential to understand the relationship between host
pathogens for better treatment. Various novel and nano-formulations using promising
technologies are being explored to deliver TB drugs via different administration routes
at right pathological site. This book addresses the gap between new and old treatment
TB modalities and how they are superior in pharmacological performance when tested
in in-vitro and in-vivo.
Audiences from a broad range of groups, from researchers, academicians, and public
health bodies to regulatory experts, can benefit from the compiled information to learn
more about patient needs and current research advances in the field of TB research.
Dr. Yashwant Pathak completed his Ph.D. in Pharmaceutical Technology from India and EMBA and MS Conflict Management from Sullivan University, USA. He is Associate Dean for Faculty Affairs College of Pharmacy, University of South Florida. Tampa, Florida. With extensive experience in academia and industry, he has over 150 research publications, abstracts, chapters and reviews, 7 books in Nanotechnology and drug delivery systems, 6 in Nutraceuticals and several books in cultural studies. His areas of research include drug delivery systems, nanotechnology applications for pharmaceutical and Nutraceuticals. He has traveled extensively over 80 countries to network scientific experts and is actively involved with many Pharmacy colleges in different countries.
- 2023, 2023, 337 Seiten, Englisch
- Herausgegeben: Ranjita Shegokar, Yashwant Pathak
- Verlag: Springer International Publishing
- ISBN-10: 3031141008
- ISBN-13: 9783031141003
- Erscheinungsdatum: 14.03.2023
Abhängig von Bildschirmgröße und eingestellter Schriftgröße kann die Seitenzahl auf Ihrem Lesegerät variieren.
- Dateiformat: PDF
- Größe: 12 MB
- Ohne Kopierschutz
- Vorlesefunktion
Zustand | Preis | Porto | Zahlung | Verkäufer | Rating |
---|
Schreiben Sie einen Kommentar zu "Tubercular Drug Delivery Systems".
Kommentar verfassen